Jean-Pierre Louboutin

Dr. Jean-Pierre Louboutin


Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2010 in Journal of Neuropathology & Experimental Neurology
Verified
Journal Article
Open access
PDF file
JLJean-Pierre Louboutin
Jean-Pierre Louboutin
LALokesh Agrawal
Lokesh Agrawal
BRBeverly A.S. Reyes
Beverly A.S. Reyes
EBElisabeth J. Van Bockstaele
Elisabeth J. Van Bockstaele
DSDavid S. Strayer
David S. Strayer
Blood-brain barrier (BBB) disruption occurs during human immunodeficiency virus encephalopathy, but the mechanisms involved are not understood. We st

1 January 2012 in The Scientific World Journal
Verified
Journal Article
Open access
PDF file
JLJean-Pierre Louboutin
Jean-Pierre Louboutin
DSDavid S. Strayer
David S. Strayer
The blood-brain barrier (BBB) is compromised in many systemic and CNS diseases, including HIV-1 infection of the brain. We studied BBB disruption caused by HIV-1 envelope glycoprotein 120 (gp120) as a model. Exposure to gp120, whether acute [by direct intra-caudate-putamen (CP) injection] or chronic [using SV(gp120), an experimental model of ongoing production of gp120] disrupted the BBB, and led to leakage of vascular contents. Gp120 was directly toxic to brain endothelial cells. Abnormalities of the BBB reflect the activity of matrix metalloproteinases (MMPs). These target laminin and attack the tight junctions between endothelial cells and BBB basal laminae. MMP-2 and MMP-9 were upregulated following gp120-injection. Gp120 reduced laminin and tight junction proteins. Reactive oxygen species (ROS) activate MMPs. Injecting gp120 induced lipid peroxidation. Gene transfer of antioxidant enzymes protected against gp120-induced BBB abnormalities. NMDA upregulates the proform of MMP-9. Using the NMDA receptor (NMDAR-1) inhibitor, memantine, we observed partial protection from gp120-induced BBB injury. Thus, (1) HIV-envelope gp120 disrupts the BBB; (2) this occurs via lesions in brain microvessels, MMP activation and degradation of vascular basement membrane and vascular tight junctions; (3) NMDAR-1 activation plays a role in this BBB injury; and (4) antioxidant gene delivery as well as NMDAR-1 antagonists may protect the BBB.

31 August 2013 in CNS & Neurological Disorders - Drug Targets
Verified
Journal Article
Closed access
JLJean-Pierre Louboutin
Jean-Pierre Louboutin
DSDavid Strayer
David Strayer
Chemokines may play a role in leukocyte migration across the blood-brain barrier (BBB) during neuroinflammation and other neuropathological processes, such as epilepsy. The CC chemokine receptor 5 (CCR5) is a member of CC-chemokine receptor family that binds several chemokines, including CCL3 (macrophage inflammatory protein-1alpha, MIP-1alpha), CCL4 (macrophage inflammatory protein-1beta, MIP-1beta) and CCL5 (RANTES). The current review examines the relationship between CCR5 and the microglia in different neurological disorders and models of CNS injury. CCR5 expression is upregulated in different neurological diseases, where it is often immunolocalized in microglial cells. A multistep cascade couples CCR5 activation by chemokines to Ca(2+) increases in human microglia. Because changes in [Ca(2+)] (i) affect chemotaxis, secretion, and gene expression, pharmacologic modulation of this pathway may alter inflammatory and degenerative processes in the CNS. Consequently, targeting CCR5 by using CCR5 antagonists may attenuate critical aspects of neuroinflammation in different models of neurological disorders. To illustrate the interaction between CCR5 and microglia in the CNS, we used a model of excitotoxicity, and demonstrate the intimate involvement of CCR5 in neuron injury and inflammation attendant to kainic acid (KA)-induced neurotoxicity. CCR5 participates in neuronal injury caused by the excitotoxin, KA, brings inflammatory cells to the sites of KA-induced CNS injury, defines the extent of tissue loss after KA exposure and limits reparative responses. We used a SV40-derived vector carrying an interfering RNA (RNAi) that targets CCR5. Delivered directly to the bone marrow, this vector decreased CCR5 expression in circulating cells. Animals so treated showed greatly reduced expression of CCR5 and its ligands (MIP-1alpha and RANTES) in the CNS, including in the brain vasculature, decreased BBB leakage, demonstrated greater KA-stimulated neurogenesis and increased migration of bone marrow-derived cells to the brain to become neurons. Thus, therapeutic targeting of CCR5 may allow control of potentially injurious neuroinflammatory responses, including decrease in microglial cells activation and proliferation, and facilitate neurogenic repair in seizure-induced and, potentially, other forms of CNS injury.

12 October 2010 in The FASEB Journal
Verified
Journal Article
Open access
PDF file
JLJean-Pierre Louboutin
Jean-Pierre Louboutin
ACAlena Chekmasova
Alena Chekmasova
ELENA MARUSICHELENA MARUSICH
ELENA MARUSICH
LALokesh Agrawal
Lokesh Agrawal
DSDavid S. Strayer
David S. Strayer
Chemokines may play a role in leukocyte migration across the blood‐brain barrier (BBB) during neuroinflammation and other neuropathological processes, such as epilepsy. We investigated the role of the chemokine receptor CCR5 in seizures. We used a rat model based on intraperitoneal kainic acid (KA) administration. Four months before KA injection, adult rats were given femoral intramarrow inoculations of SV (RNAiR5‐RevM10.AU1), which carries an interfering RNA (RNAi) against CCR5, plus a marker epitope (AU1), or its monofunctional RNAi‐carrying homologue, SV(RNAiR5). This treatment lowered expression of CCR5 in circulating cells. In control rats, seizures induced elevated expression of CCR5 ligands MIP‐1α and RANTES in the microvasculature, increased BBB leakage and CCR5 + cells, as well as neuronal loss, inflammation, and gliosis in the hippocampi. Animals given either the bifunctional or the monofunctional vector were largely protected from KA‐induced seizures, neuroinflammation, BBB damage, and neuron loss. Brain CCR5 mRNA was reduced. Rats receiving RNAiR5‐bearing vectors showed far greater repair responses: increased neuronal proliferation, and decreased production of MIP‐1α and RANTES. Controls received unrelated SV(BUGT) vectors. Decrease in CCR5 in circulating cells strongly protected from excitotoxin‐induced seizures, BBB leakage, CNS injury, and inflammation, and facilitated neurogenic repair.—Louboutin, J.‐P., Chekmasova, A., Ma‐rusich, E., Agrawal, L., Strayer, D. S. Role of CCR5 and its ligands in the control of vascular inflammation and leukocyte recruitment required for acute excitotoxic seizure induction and neural damage. FASEB J. 25, 737–753 (2011). www.fasebj.org

17 October 2010 in Nature Methods
Verified
Journal Article
Closed access
JLJean-Pierre Louboutin
Jean-Pierre Louboutin
ACAlena A Chekmasova
Alena A Chekmasova
ELENA MARUSICHELENA MARUSICH
ELENA MARUSICH
JCJ Roy Chowdhury
J Roy Chowdhury
DSDavid S Strayer
David S Strayer

1 January 2010 in Experimental Neurology
Verified
Journal Article
Closed access
JLJean-Pierre Louboutin
Jean-Pierre Louboutin
BRBeverly A.S. Reyes
Beverly A.S. Reyes
LALokesh Agrawal
Lokesh Agrawal
EBElisabeth J. Van Bockstaele
Elisabeth J. Van Bockstaele
DSDavid S. Strayer
David S. Strayer